clinical trial · NCT06971185
A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept
Bristol-Myers Squibb·—·completed·n = 430
Myelodysplastic Syndromes (MDS)LuspaterceptErythropoiesis-stimulating agent (ESA)
brief summary
The purpose of this study is to understand the treatment patterns and clinical outcomes of myelodysplastic syndromes patients treated with luspatercept or erythropoiesis-stimulating agents
started
Nov 22, 2024
primary completion
Aug 1, 2025
completion
Aug 1, 2025
last updated
Sep 30, 2026
official title
Treatment Patterns and Effectiveness of Luspatercept in the Real World
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol